Endometriosis: Pathogenesis and Treatment 2014 Ed.

14. Endometriosis in Experimental Models

Fuminori Taniguchi  and Tasuku Harada1

(1)

Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan

Fuminori Taniguchi

Email: tani4327@med.tottori-u.ac.jp

Abstract

To investigate the factors involved in the initiation and progression of endometriosis, an animal model of this disease has been employed. Animal models are often used to investigate factors affecting the initiation and progression of endometriosis. This chapter describes these models and focuses on the murine model of endometriosis as a potential tool to evaluate therapies. The traditional explanation for the existence of endometrium in ectopic locations is based on the common occurrence of retrograde menstruation. This implantation hypothesis is widely accepted as the etiology of endometriosis. Animal models are crucial for elucidating the mechanisms underlying endometriosis. Several animal models of endometriosis have been used in the past, most of which consist of transplanting endometrium into the peritoneal cavity. Because primates spontaneously develop endometriosis, primate models most closely resemble the disease in women; however, rodent models are more cost effective and readily available. Nevertheless, since rodents do not menstruate, rodent models used for the research in endometriosis have certain limitations. We addressed the question whether a murine endometriosis model is suitable for evaluating drugs employed in human endometriosis. We concluded that the murine endometriosis model may be a valuable and reliable tool for evaluating new therapeutic approaches in human endometriosis.

Keywords

Cystic lesionExperimental modelMouse endometriosis-like lesionParthenolide

The authors have no conflicts to disclose relative to this work.

14.1 Introduction

Endometriosis is commonly believed to occur via retrograde menstruation, also known as the Sampson hypothesis [1], in which viable endometrial tissue flows retrograde through the fallopian tube and into the peritoneal cavity where it can attach to and invade tissues and organs within the cavity. At least 90 % of women experience retrograde menstruation, but endometriosis occurs in only 10–14 % of reproductive age women, suggesting that additional elements impact its etiology [2]. Since endometriosis impairs the quality of life of severely affected women, improved research and new treatment paradigms are needed.

Current medical therapies for endometriosis aim to decrease ovarian estrogen production and/or counteract estrogen effects with the use of GnRH agonists, progestins (including oral contraceptives), and androgens, but undesirable side effects limit their long-term use [2]. Likewise, the scope of surgical treatment is also limited by a high recurrence rate, which may eventually lead to extreme measures, such as removal of the uterus and ovaries. There is therefore a need for focused mechanistic research that can be translated into expanded therapeutic capability for this widely prevalent disease.

Animal models, which are important for elucidating the mechanisms underlying endometriosis and are used in the early stages of drug testing, usually rely on non-menstruating rodents with induced endometriosis-like lesions. One of the major limitations in endometriosis research is the paucity of robust animal disease models. Ideally, a disease model should mimic human disease and allow scientific investigation into the effects of both intrinsic (e.g., genes) and extrinsic (e.g., environment) factors on disease progression.

Several animal models of endometriosis have been established, most consisting of transplantation of endometrium into the peritoneal cavity, which is by far the most common site of disease. Besides rodents, primates, such as monkeys that spontaneously develop endometriosis or that have been transplanted intraperitoneally with endometrium, can be used to study drug candidates. Indeed, because endometriosis occurs spontaneously in monkeys, the only nonhuman animal model that has cyclic menstrual periods, such an animal model is undoubtedly the most reliable one [37]. However, high cost and difficulties maintaining these animals have led most researchers to concentrate their studies on smaller mammalian models, such as rats [812] and rabbits [1314]. Nevertheless, the murine model was considered as a possible candidate for this purpose, and these studies were restricted to nude [1516] or SCID mice [17], which were implanted with human endometrium (xenotransplantation). Since mice are much smaller than rabbits or rats, microsurgical procedures of tissue transplantation become even more complicated.

The murine model may provide advantages in terms of new therapeutic approaches. In recent decades, many knockout or transgenic mice have been generated. The availability of an endometriosis model in mice is crucial because it can be used to investigate some aspects of endometriosis.

14.2 Murine Endometriosis Model

Mice are the most common animal models capable of investigating the pathophysiology of endometriosis; however, they do not spontaneously develop endometriosis. To induce endometriosis in mice, endometrial tissue must be transplanted into the peritoneal cavity using several methods [1821], which can be classified into two basic types, homologous and heterologous. Both models produce comparable phenotypes, which are then morphometrically evaluated.

In homologous or autologous models, normal endometrial tissue is transplanted into the peritoneal cavity of immunocompetent recipients and starts to grow in an estrogen-dependent manner. In almost all models, uterine endometrial fragments from a donor mouse are directly introduced via injection into the peritoneal cavity of an immunocompetent syngeneic recipient without suturing the implants. In heterologous models, human endometriotic lesions are transplanted into the peritoneal cavity of immunodeficient mice [2223]. Human endometriotic implants were sutured to the peritoneum of immunocompromised mice [2425]. This xenotransplantation model using the nude mouse is also used, but is limited by the lack of a normal immune system. Despite the advantage of being based on human endometrial tissues, the number of endometriotic lesions in the heterologous model that will develop varies from one animal to another. In both models, with or without suturing the endometrial implant, the drug’s influence on growth of endometrial or endometriotic transplants is evaluated.

These established endometriosis models in mice are under discussion. Indeed, mice do lack a menstrual cycle and do not develop spontaneous endometriosis. It should be established whether transplanting normal endometrium into the peritoneal cavity of a non-menstruating species reflects all pathophysiological aspects of human endometriosis. Although the murine endometriosis model is not exactly the same as human endometriosis, their endometriotic lesions develop in some ways the same as human endometriotic lesions.

The murine model of endometriosis is a versatile one used to study how the immune system, hormones, and environmental factors affect endometriosis and how endometriosis affects fertility and pain. A novel study design also enables the evaluation of molecular mechanisms that are critical for disease initiation [2627]. In Table 14.1, the recent representatives of mouse endometriosis models are shown. Additional and ideal models of endometriosis are needed. In the next section, we demonstrate the results in a murine endometriosis model that expands the capability of conducting both mechanistic and translational research.

Table 14.1

Representatives of mouse endometriosis models

Author (year)

Donor

Host

Drug

Characteristics of models

References

Takai et al. (2013)

M

M

Parthenolide

Large cyst formation

[28]

Sokalska et al. (2013)

H

M

Simvastatin

 

[29]

Daftary et al. (2013)

M

M

 

Adhesion scoring system

[30]

Rudzitis-Auth et al. (2013)

M

M

Resveratrol

 

[31]

Burns et al. (2012)

M

M

 

Estrogen receptor KO

[27]

Novella-Maestre et al. (2012)

H

NM

Cabergoline

Assessment nerve fibers

[32]

Han et al. (2012)

M

M

 

SRC-1 KO

[33]

Mariani et al. (2012)

M

M

Vitamin D receptor agonist

 

[34]

Wieser et al. (2012)

M

M

Retinoic acid

GFP mice

[35]

Cakmak et al. (2012)

M

M

Statins

 

[36]

Leconte et al. (2011)

M

M

Temsirolimus

Deep infiltrating implants

[37]

Olivares et al. (2011)

M

M

Celecoxib, Rosiglitazone

 

[38]

Kulak Jr et al. (2011)

M

M

Bazedoxifene

 

[39]

Lu et al. (2010)

M

M

Trichostatin A

Autotransplant model

[40]

Styer et al. (2008)

M

M

Leptin receptor antagonist

 

[26]

Hirata et al. (2005)

M

M

 

GFP mice

[21]

M mouse, H human, NM nude mouse, KO knockout mouse, GFP green fluorescent protein

14.3 Our Animal Model of Endometriosis Using Homologous Mice

14.3.1 Care and Treatment

According to the implantation theory, we established the readily available murine model to evaluate the development of endometriosis-like lesions [2728]. Female mice (6 weeks of age, BALB/c) were purchased. Before initiating the experiments, animals were allowed to acclimate to the following conditions for 7 days. Mice were in a controlled temperature range (72–74 F) on a 12-h light, 12-h dark cycle. Mice were given food and water ad libitum. Recipient mice were ovariectomized through two 0.5-cm dorsolateral skin incisions and were then divided into two treatment groups, estradiol valerate (0.5 μg/mouse · week) in corn oil or only corn oil vehicle. Mice were dosed subcutaneously once per week for 2 weeks before inducing experimental endometriosis. Donor mice were primed 41 h before removing the uterus with pregnant mare serum gonadotropin (10 IU intraperitoneally). The donor uterus was removed en bloc after euthanasia, cleaned of excess tissue, and washed thrice in sterile PBS. The uterus was slit with a linear incision longitudinally and minced (≤1.5 mm). Recipient mice were anesthetized using isoflurane/oxygen and given buprenorphine (0.1 mg/kg) for pain management. A 0.5-cm right dorsolateral incision was made; minced donor tissue (1:2 donor uterus to host ratio) in 500 μL PBS was injected into the peritoneal cavity of the recipient and gently massaged to disperse the tissue. An equivalent amount (~100 mg) of minced tissue was transferred into all recipients. Mice were treated for 4 additional weeks with estradiol valerate or the vehicle. After 4 weeks, mice were euthanized with CO2, the peritoneal cavity was opened, and endometriosis-like lesions were removed. To assess the effects of drug candidates on ectopic uterine tissue, ectopic lesions were photographed to document in situ endometriosis-like lesions. Endometriosis-like lesions were visualized, dissected, measured, and weighed. Endometriosis-like lesions were removed and either fixed in 10 % formalin or snap-frozen on dry ice and stored at −80 °C until use.

14.4 Effects of Parthenolide on the Endometriosis-Like Lesions in a Murine Model

We undertook a study of feverfew as a potential therapy for endometriosis that illustrated the effectiveness of the murine model. The medical herb feverfew has long been used as a folk medicine for treating fevers, migraine, rheumatoid arthritis, and dysmenorrhea. Parthenolide is considered the primary bioactive compound in feverfew having antitumor and anti-inflammatory properties [41]. Parthenolide has produced anti-tumorigenesis effects against human acute myeloid leukemia and solid tumors, such as breast and pancreatic cancer [4244]. We therefore used an experimental mouse model to evaluate the effect of parthenolide as therapy for endometriosis [28].

A murine model was established by injecting tissue suspension intraperitoneally. Endometriosis-like lesions had grown in the abdominal cavity of all mice. The deposits appeared as cystic lesions bulging under the serosal coat. Most of the lesions were observed around the abdominal incision, the intestinal membrane, and the renal capsule (Fig. 14.1a). The size of lesions ranged from approximately 2 to 8 mm in diameter (Fig. 14.1b). Histologic sections stained with hematoxylin and eosin were endometriotic in character. The monolayer epithelial cell lining of the cyst was revealed by HE staining (Fig. 14.1c, d) [28]. We confirmed that cytokeratin (a marker of epithelial cells) and vimentin (a marker of stromal cells) in the mouse endometriosis-like lesions were positive, whereas calretinin (that of mesothelial cells) was negative, indicating that these cystic lesions originated from the injected endometrial tissues, not the peritoneal cells.

A313895_1_En_14_Fig1_HTML.jpg

Fig. 14.1

Cystic lesion in the murine endometriosis model. (a) An endometriosis-like lesion developed in the murine abdominal cavity. (b) Representative of a large excised lesion. (c) and (d) HE staining of lesion

In view of the above considerations, we proposed a hypothesis that parthenolide may have an inhibitory effect on the development of endometriosis. After parthenolide treatment for 4 weeks, the total number of lesions (5.8 vs. 3.9/mouse) was significantly reduced, and the average weight (65.6 vs. 29.6 mg/mouse) and the surface area (50.3 vs. 25.7 mm2/mouse) of lesions were decreased by approximately 50 % of controls. To evaluate the proliferative activity of lesions, the ratio of Ki67-stained cells was calculated. In endometrial glands epithelia, the percentage of Ki67-positive cells decreased after parthenolide treatment (17.8 vs. 8.5 %).

14.5 Discussion

Convenient and reliable endometriosis animal models are needed to accelerate emerging therapeutic alternatives. According to the Sampson “implantation theory,” we established the syngeneic immunocompetent mice model. In this model, we and the other investigators provided crucial evidence of both the development of endometriosis-like lesion growth and donor tissue responsiveness. Recently, Pelch et al. described a detailed method of a mouse surgically induced endometriosis model by autotransplantation of uterine tissue [45].

The rodent endometriosis models using mice or rats are widely used in research, but may have limitations and may not mimic all aspects of human pathophysiology. For example, in homologous rodent models, “healthy” uterus is cut into fragments and transplanted into the peritoneum, whereas it has been suggested that the eutopic endometrium of women suffering from endometriosis may already be abnormal [2]. Nude mice lacking an intact immune system are employed in the heterologous model, which cannot mimic the inflammatory response normally seen in human endometriotic lesions [23]. Although heterologous rodent endometriosis models are responsive to drugs and manipulations that induce a hypoestrogenic state, such as ovariectomy, GnRH agonists, aromatase inhibitors, danazol, and selective estrogen receptor modulators, it may be difficult to analyze novel target families in which, for example, the murine ligand does not bind to the receptor of the human transplant.

Whereas cell-based in vitro experiments provide a framework for testing molecular mechanisms, eventually confirming their role in disease causality in vivo can only be accomplished by a suitable animal model. For a disease as diverse as endometriosis, a single animal model would unlikely be sufficient to represent the entire diversity in etiology, pathogenesis, and pathology. Each model has design-related strengths and limitations. For example, a recently described disease model consists of introducing endometrial tissue via direct injection into the peritoneal cavity of immunocompetent mice without suturing [212728]. In mice, the injected tissue forms cyst-like endometriosis lesions; however, the injection method does not seem to work in rats because the tissue fails to attach to and invade the peritoneal cavity [9]. Since all endometriosis lesions in each model are attached to the peritoneum and/or mesenterium with or without suturing, evaluating attachment or invasion of lesions would be difficult. Furthermore, to quantify the injected endometrial fragments, this model may be insufficient to evaluate precisely the endometriotic lesions.

The rodent model is used extensively to study the etiology, pathology, and risk factors of endometriosis [2122273033354647] as well as to explore novel therapeutics [282931323436404851]. In conclusion, this murine model of endometriosis provides an important tool to evaluate a therapeutic approach to the disease. This model will help to better understand disease evolution in the living animal and permit faster and more accurate characterization of a drug’s effect on experimental endometriosis.

References

1.

Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3:93–110.43.PubMedCentralPubMed

2.

Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789–99.PubMedCrossRef

3.

MacKenzie WF, Casey HW. Animal model of human disease. Endometriosis. Animal model: endometriosis in rhesus monkeys. Am J Pathol. 1975;80:341–4.PubMedCentralPubMed

4.

Scott RB, Te Linde RW, Wharton Jr LR. Further studies on experimental endometriosis. Am J Obstet Gynecol. 1953;66:1082–103.PubMed

5.

Donnez O, Soares M, Defrere S, Dehoux JP, van Langendonckt A, et al. Nerve fiber density in deep nodular endometriotic lesions induced in a baboon experimental model. Fertil Steril. 2013;100(4):1144–50.PubMedCrossRef

6.

Langoi D, Pavone ME, Gurates B, Chai D, Fazleabas A, et al. Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons. Fertil Steril. 2013;99(656–662):e653.

7.

Lebovic DI, Mwenda JM, Chai DC, Santi A, Xu X, et al. Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology. 2010;151:1846–52.PubMedCentralPubMedCrossRef

8.

Golan A, Dargenio R, Winston RM. The effect of treatment on experimentally produced endometrial peritoneal implants. Fertil Steril. 1986;46:954–8.PubMed

9.

Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44:684–94.PubMed

10.

Abbas MA, Taha MO, Disi AM, Shomaf M. Regression of endometrial implants treated with vitamin D in a rat model of endometriosis. Eur J Pharmacol. 2013;715:72–5.PubMedCrossRef

11.

Stilley JA, Sharpe-Timms KL. TIMP1 contributes to ovarian anomalies in both an MMP-dependent and -independent manner in a rat model. Biol Reprod. 2012;86:47.PubMedCentralPubMedCrossRef

12.

Yuan P, Chen B, Huang Y, Xin X. Long-term regression of experimental endometriosis in a rat model treated with local application of levonorgestrel-loaded biodegradable microspheres. Hum Reprod. 2012;27:2089–95.PubMedCrossRef

13.

Rock JA, Prendergast RA, Bobbie D, Green WR, Parmley TH, et al. Intraocular endometrium in the rabbit as a model for endometriosis. Fertil Steril. 1993;59:232–5.PubMed

14.

Yuan P, Huang Y, Wu H, Teng Z, Zhang J, et al. Induction of a local pseudo-pregnancy via levonorgestrel-loaded microspheres for the treatment of endometriosis in a rabbit model. Hum Reprod. 2010;25:462–9.PubMedCrossRef

15.

Zamah NM, Dodson MG, Stephens LC, Buttram Jr VC, Besch PK, et al. Transplantation of normal and ectopic human endometrial tissue into athymic nude mice. Am J Obstet Gynecol. 1984;149:591–7.PubMedCrossRef

16.

Fortin M, Lepine M, Merlen Y, Thibeault I, Rancourt C, et al. Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. Mol Ther. 2004;9:540–7.PubMedCrossRef

17.

Aoki D, Katsuki Y, Shimizu A, Kakinuma C, Nozawa S. Successful heterotransplantation of human endometrium in SCID mice. Obstet Gynecol. 1994;83:220–8.PubMed

18.

Cummings AM, Metcalf JL. Induction of endometriosis in mice: a new model sensitive to estrogen. Reprod Toxicol. 1995;9:233–8.PubMedCrossRef

19.

Grummer R, Schwarzer F, Bainczyk K, Hess-Stumpp H, Regidor PA, et al. Peritoneal endometriosis: validation of an in-vivo model. Hum Reprod. 2001;16:1736–43.PubMedCrossRef

20.

Rossi G, Somigliana E, Moschetta M, Santorsola R, Cozzolino S, et al. Dynamic aspects of endometriosis in a mouse model through analysis of implantation and progression. Arch Gynecol Obstet. 2000;263:102–7.PubMedCrossRef

21.

Hirata T, Osuga Y, Yoshino O, Hirota Y, Harada M, et al. Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod. 2005;20:2092–6.PubMedCrossRef

22.

Story L, Kennedy S. Animal studies in endometriosis: a review. ILAR J. 2004;45:132–8.PubMedCrossRef

23.

Tirado-Gonzalez I, Barrientos G, Tariverdian N, Arck PC, Garcia MG, et al. Endometriosis research: animal models for the study of a complex disease. J Reprod Immunol. 2010;86:141–7.PubMedCrossRef

24.

Lee B, Du H, Taylor HS. Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium. Biol Reprod. 2009;80:79–85.PubMedCentralPubMedCrossRef

25.

Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, et al. Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab. 2002;87:4782–91.PubMedCrossRef

26.

Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, et al. Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology. 2008;149:506–14.PubMedCentralPubMedCrossRef

27.

Burns KA, Rodriguez KF, Hewitt SC, Janardhan KS, Young SL, et al. Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology. 2012;153:3960–71.PubMedCentralPubMedCrossRef

28.

Takai E, Taniguchi F, Nakamura K, Uegaki T, Iwabe T, et al. Parthenolide reduces cell proliferation and prostaglandin E synthesis in human endometriotic stromal cells and inhibits development of endometriosis in the murine model. Fertil Steril. 2013;100(4):1170–8.PubMedCrossRef

29.

Sokalska A, Anderson M, Villanueva J, Ortega I, Bruner-Tran KL, et al. Effects of simvastatin on retinoic acid system in primary human endometrial stromal cells and in a chimeric model of human endometriosis. J Clin Endocrinol Metab. 2013;98:E463–71.PubMedCentralPubMedCrossRef

30.

Daftary GS, Zheng Y, Tabbaa ZM, Schoolmeester JK, Gada RP, et al. A novel role of the Sp/KLF transcription factor KLF11 in arresting progression of endometriosis. PLoS One. 2013;8:e60165.PubMedCentralPubMedCrossRef

31.

Rudzitis-Auth J, Menger MD, Laschke MW. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum Reprod. 2013;28:1339–47.PubMedCrossRef

32.

Novella-Maestre E, Herraiz S, Vila-Vives JM, Carda C, Ruiz-Sauri A, et al. Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers. Fertil Steril. 2012;98:1209–17.PubMedCrossRef

33.

Han SJ, Hawkins SM, Begum K, Jung SY, Kovanci E, et al. A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nat Med. 2012;18:1102–11.PubMedCentralPubMedCrossRef

34.

Mariani M, Vigano P, Gentilini D, Camisa B, Caporizzo E, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012;27:2010–9.PubMedCrossRef

35.

Wieser F, Wu J, Shen Z, Taylor RN, Sidell N. Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis. Fertil Steril. 2012;97:1430–7.PubMedCentralPubMedCrossRef

36.

Cakmak H, Basar M, Seval-Celik Y, Osteen KG, Duleba AJ, et al. Statins inhibit monocyte chemotactic protein 1 expression in endometriosis. Reprod Sci. 2012;19:572–9.PubMedCentralPubMedCrossRef

37.

Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179:880–9.PubMedCentralPubMedCrossRef

38.

Olivares C, Ricci A, Bilotas M, Baranao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96:428–33.PubMedCrossRef

39.

Kulak Jr J, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011;152:3226–32.PubMedCentralPubMedCrossRef

40.

Lu Y, Nie J, Liu X, Zheng Y, Guo SW. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod. 2010;25:1014–25.PubMedCrossRef

41.

Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol. 1999;68:251–9.PubMedCrossRef

42.

Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–9.PubMedCentralPubMedCrossRef

43.

Liu JW, Cai MX, Xin Y, Wu QS, Ma J, et al. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29:108.PubMedCentralPubMed

44.

Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005;4:1004–12.PubMedCrossRef

45.

Pelch KE, Sharpe-Timms KL, Nagel SC. Mouse model of surgically-induced endometriosis by auto-transplantation of uterine tissue. J Vis Exp. 2012;59:e3396 doi 10.​3791/​3396.

46.

Cummings AM, Hedge JM, Birnbaum LS. Effect of prenatal exposure to TCDD on the promotion of endometriotic lesion growth by TCDD in adult female rats and mice. Toxicol Sci. 1999;52:45–9.PubMedCrossRef

47.

Sharpe-Timms KL, Piva M, Ricke EA, Surewicz K, Zhang YL, et al. Endometriotic lesions synthesize and secrete a haptoglobin-like protein. Biol Reprod. 1998;58:988–94.PubMedCrossRef

48.

Yavuz E, Oktem M, Esinler I, Toru SA, Zeyneloglu HB. Genistein causes regression of endometriotic implants in the rat model. Fertil Steril. 2007;88:1129–34.PubMedCrossRef

49.

Dmitrieva N, Nagabukuro H, Resuehr D, Zhang G, McAllister SL, et al. Endocannabinoid involvement in endometriosis. Pain. 2010;151:703–10.PubMedCentralPubMedCrossRef

50.

Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril. 2005;83:171–81.PubMedCrossRef

51.

Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, et al. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril. 2006;85:71–7.PubMedCrossRef